Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 25,281 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 25,281 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $1.87, for a total transaction of $47,275.47. Following the completion of the transaction, the insider directly owned 3,496,907 shares of the company’s stock, valued at approximately $6,539,216.09. The trade was a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Up 10.1%

Shares of NASDAQ DYAI opened at $1.06 on Tuesday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. Dyadic International Inc. has a 1 year low of $0.65 and a 1 year high of $1.35. The stock’s 50-day simple moving average is $0.77 and its 200-day simple moving average is $0.83. The firm has a market cap of $38.81 million, a price-to-earnings ratio of -4.70 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, equities analysts anticipate that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Trending Headlines about Dyadic International

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations continue to validate its C1 protein-expression platform and expand its commercial opportunity, reinforcing the investment case around its core biotechnology technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: The company’s latest reported quarterly results were mixed, with revenue beating expectations but earnings per share missing estimates, leaving investors focused on future commercialization progress rather than near-term profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreemen disclosed additional stock sales, adding to recent insider selling that may create some caution around the stock’s near-term momentum.

Hedge Funds Weigh In On Dyadic International

A number of hedge funds have recently added to or reduced their stakes in the business. Apis Capital Advisors LLC bought a new stake in Dyadic International during the third quarter valued at $1,817,000. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International in the 3rd quarter valued at about $190,000. Marathon Capital Management grew its position in shares of Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the period. Institutional investors and hedge funds own 27.95% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dyadic International has a consensus rating of “Hold” and a consensus price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.